Literature DB >> 12535840

Validation of a simple gas chromatographic-mass spectrometric method for the determination of gamma-butyrolactone in human plasma.

Yousuke Fukui1, Eiji Matsusima, Kouichi Muramoto, Nobutaka Nagai, Koso Ohama, Kazumasa Yamashita.   

Abstract

A gas chromatographic-mass spectrometric (GC-MS) method is described for the determination of human plasma levels of gamma-butyrolactone (GBL) is described. The method is sensitive and simple. The plasma sample spiked with the internal standard was extracted by dichloromethane (CH(2)Cl(2)) in acidic conditions, and the concentrated organic layer was injected into GC-MS. Because of endogenous GBL in human plasma, the method used a standard calibration curve. The calibration curve was linear from 10 to 1000 ng/ml. The method has been validated for accuracy and precision with the relative error and C.V. for intra- and inter-day within 10%. GBL-spiked plasma samples stored at -80 degrees C were stable for a 3-month period. The stability of plasma samples after three cycles of freezing and thawing and of prepared samples on an autosampler for 48 h were demonstrated. Plasma concentrations of GBL before and after administration of UFT were 24.3+/-14.2 and 84.9+/-22.4 ng/ml, respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535840     DOI: 10.1016/s1570-0232(02)00858-9

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.

Authors:  Nobutaka Nagai; Keiji Mukai; Eiji Hirata; Hong Hua Jin; Masaaki Komatsu; Mayu Yunokawa
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

2.  Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.

Authors:  Wakako Tsuji; Hiroshi Ishiguro; Sunao Tanaka; Megumi Takeuchi; Takayuki Ueno; Masakazu Toi
Journal:  Int J Clin Oncol       Date:  2013-06-06       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.